Gynomax

Candidal vulvovaginitis caused by Candida albicans, bacterial vaginosis caused by Gardnerella vaginalis & anaerobic bacteria, trichomonal vaginitis caused by Trichomonas vaginalis, & mixed vag infections.

Adult & elderly >65 yr Insert 1 supp high into the vag at night for 3 days.

Hypersensitivity to tioconazole, tinidazole, lidocaine or their derivatives. Patients w/ organic neurologic disorders; current picture or history of blood dyscrasia. 1st trimester of pregnancy. Lactation.

Not to be swallowed or applied by other routes. Administration during menstruation is not recommended. Transient leukopenia & neutropenia may develop. Warn patients not to take alcohol during therapy & for 3 days after end of a treatment course. Should not be used in virgins & in young girls who are not sexually mature. Must not be used w/ contraceptive diaphragms & condoms or other vag products (eg, tampon, douche or spermicide) during treatment. Sexual partners w/ Trichomonas vaginalis should be treated at the same time. Patients w/ CV disorders; hepatic &/or renal failure. Avoid pregnancy. Usage during 2nd & 3rd trimesters must be evaluated according to benefits/risks ratio; not to be used during pregnancy unless clearly necessary. Should not be used in childn <12 yr.

Weakness, fatigue, malaise, headache, dizziness; metallic/bitter taste, nausea, anorexia, loss of appetite, flatulence, dyspepsia, abdominal cramp, epigastric discomfort, vomiting, constipation; darkened urine.

Tinidazole: Increased bleeding risk w/ acenocoumarol, anisindione, dicoumarol, phenindione, phenprocoumon, warfarin. Decreased efficacy w/ cholestyramine; CYP3A4 inducers. Increased plasma conc w/ cimetidine; ketoconazole. Increased levels of cyclosporine; tacrolimus. CNS-related effects (eg, psychotic reactions) w/ disulfiram. Increased plasma levels of fluorouracil & signs of a potential fluorouracil intoxication (granulocytopenia, anemia, thrombocytopenia, stomatitis, vomiting). Increased toxicity of fosphenytoin &/or decreased plasma conc of tinidazole w/ fosphenytoin. Increased plasma conc of lithium & signs of lithium intoxication (weakness, shaking, polydipsia, confusion). Decreased plasma conc w/ phenobarb; rifampin. Increased potential phenytoin intoxication &/or decreased plasma conc of tinidazole w/ phenytoin. Increased risk of adverse reactions w/ CYP3A4 inhibitors eg, cimetidine & ketoconazole. Tioconazole: Increased plasma conc & decreased clearance of oxycodone. Lidocaine: Decreased plasma clearance w/ propranolol; cimetidine. Increased lidocaine toxicity w/ antiarrhythmic products. Decreased plasma level of phenytoin or barbiturates.

Preparations for Vaginal Conditions

G01AF20 - combinations of imidazole derivatives ; Belongs to the class of imidazole derivative antiinfectives. Used in the treatment of gynecological infections.

Rx